Treatment with tovecimig, formerly known as CTX-009, elicited responses in patients with biliary tract cancer, according to ...

Tovecimig, formerly known as CTX-009, is a bispecific antibody that blocks the Delta-like ligand 4 and vascular endothelial growth factor A signaling pathways.

Bile duct inflammation and scarring, known as cholangiopathies, can disrupt bile flow, leading to liver damage and ...

Ceramide metabolism has garnered increasing attention in liver diseases, but its role in cholestatic liver injury remains unclear. Here the authors show that targeting ACER3, a ceramidase ...

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one ...

Primary biliary cholangitis (PBC), also known as primary biliary cirrhosis, is a chronic and progressive disease that damages ... such as urinary tract infections (UTIs). Primary biliary ...

liver disease, biliary tract disorders, and pancreatic disease. By modulating crucial signaling pathways, tsRNAs could serve as early diagnostic markers and therapeutic targets, transforming ...

Compass Therapeutics' Phase 2/3 trial shows tovecimig plus paclitaxel significantly improves response rates in advanced biliary tract cancer patients.

Medically reviewed by Jay N. Yepuri, MD While the occasional appearance of clay-colored stool (poop) isn't typically a cause for concern, persistently pale stool may indicate something is wrong with ...

Biliary tract cancer occurs in the bile ducts and ... with just 5% to 15% of patients expected to live beyond five years. The disease can be asymptomatic in the early stages, so patients have ...

FGFR1-targeting Pemazyre was approved by the FDA for previously treated biliary tract tumours with FGFR2 gene fusions in 2020, becoming the first targeted therapy for the disease, and last year ...